{
    "clinical_study": {
        "@rank": "87165", 
        "arm_group": [
            {
                "arm_group_label": "LCP-Tacro", 
                "arm_group_type": "Experimental", 
                "description": "LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)"
            }, 
            {
                "arm_group_label": "Prograf", 
                "arm_group_type": "Active Comparator", 
                "description": "Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets\n      administered once-daily compared to Prograf capsules administered twice-daily after kidney\n      transplantation."
        }, 
        "brief_title": "A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Failure", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "This is a 2-arm , parallel group, prospective, double-blind, double-dummy,\n      multicenter,clinical trial to evaluate the pharmacokinetics of LCP-Tacro tablets once daily\n      in comparison to Prograf capsules twice-daily after kidney transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be able to give written consent.\n\n          -  Male and female subjects between the ages of 18 and 70 years, inclusive.\n\n          -  Subjects must be receiving primary or secondary renal allograft from a deceased donor\n             or non-HLA identical living donor.\n\n          -  Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or\n             urine pregnancy test with a sensitivity of a least 25 mIU/ml) within 1 week prior to\n             randomization or in accordance with local regulations, whichever is of shorter\n             duration.  All subjects must agree to follow the contraceptive guidelines as detained\n             in section 8.2.4.\n\n          -  Subjects must have negative cross-match test and be ABO-compatible.\n\n          -  Subjects must be able to swallow tablets and capsules\n\n        Exclusion Criteria:\n\n          -  Subjects who are recipients of any previous non-renal concurrent transplant (solid\n             organ or bone marrow)\n\n          -  Subjects who have panel reactive antibody > 50%\n\n          -  Subjects with any condition that may affect study drug absorption (eg, gastrectomy or\n             clinically significant diabetic gastroenteropathy, inflammatory bowel disease, or\n             gastric bypass)\n\n          -  Subjects with body mass index (BMI) , 18 kg/m2 or > 45 kg/m2, calculated using the\n             formula of BMI = mass/(height2)\n\n          -  Subjects with history of alcohol abuse with less than 6 months of sobriety\n\n          -  Subjects with history  of recreational drug abuse with less than 6 months of\n             documented abstinence\n\n          -  Subjects with screening 12-lead ECG demonstrating clinically significant\n             abnormalities (including QTc prolongation)\n\n          -  Subjects who are WOCBP and are either pregnant, lactating, planning to become\n             pregnant or with a positive serum or urine pregnancy test\n\n          -  Subjects (male  or female) with reproductive potential who are unwilling/unable to\n             use a double-barrier method of contraception and follow the contraception guidelines\n             in 8.2.4\n\n          -  Subjects with an oral temperature (prior to study drug dosing) of 38C (100.4F) or\n             higher\n\n          -  Subjects with clinically significant active infections (eg, those requiring\n             hospitalization, or as judged by the Investigator)\n\n          -  Subjects with known hereditary immunodeficiency\n\n          -  Subjects with malignancies or with a history of malignancies (within the last 5\n             years) with the exception of local, noninvasive, fully excised cutaneous basal cell\n             carcinoma, cutaneous squamous cell carcinoma, or cervical carinoma in situ\n\n          -  Subjects who expect to receive within 2 months after randomization, or have received\n             within 3 months prior to screening, any of the following: sirolimus, everolimus,\n             belatacept, or cyclophosphamide\n\n          -  Subjects with any psychiatric or medical condition (cardiac, pulmonary, central\n             nervous system, gastrointestinal, endocrine/metabolic, etc) that, in the\n             Investigator's opinion, may put the subject at significant risk, may confound the\n             study results, or may interfere significantly with the subject's participation in the\n             study\n\n          -  Subjects with clinically symptomatic congestive heart failure or documented rejection\n             fraction of less than 45%\n\n          -  Subjects with significant chronic obstructive pulmonary disease, pulmonary\n             restrictive disease or significant pulmonary hypertension\n\n          -  Subjects currently enrolled in another investigational drug or device study, who are\n             less than 30 days since discontinuing another investigational drug or device study,\n             or who are currently receiving other investigational treatment\n\n          -  Subjects with laboratory variables that are abnormal (outside laboratory reference\n             range) and clinically significant as judged by the Investigator\n\n          -  Subjects with positive results of any of the following serological tests: human\n             immunodeficiency virus (HIV)-1 antibody, hepatitis B virus (HBV) surface antigen\n             (HBsAg), anti-hepatitis B core antibody (HBcAb), and anti-hepatitis C virus (HCV)\n             antibody (HCV Ab). Negative results for these serological tests much be documented\n             within 12 months prior to randomization\n\n          -  Subjects who have had primary focal segmental glomerulosclerosis\n\n          -  Donor parameters must not include any of the following known conditions:\n\n        Positive serological test result for HIV-1, HBV or HCV History of malignant disease\n        (current or historical) Cold ischemia time > 30 hours Non-heart-beating donor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666951", 
            "org_study_id": "LCP-Tacro 2019"
        }, 
        "intervention": [
            {
                "arm_group_label": "LCP-Tacro", 
                "description": "Tacrolimus", 
                "intervention_name": "LCP-Tacro tablets", 
                "intervention_type": "Drug", 
                "other_name": "Prograf"
            }, 
            {
                "arm_group_label": "Prograf", 
                "description": "Tacrolimus", 
                "intervention_name": "Prograf", 
                "intervention_type": "Drug", 
                "other_name": "Prograf Capsules twice daily"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Clinical Investigative Site 000015"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Clinical Investigative Site 000012"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Clinical Investigative Site 00004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "Clinical Investigative Site 000002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40536-0293"
                    }, 
                    "name": "Clinical Investigative Site 000005"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Clinical Investigative Site 000009"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Livingston", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07039"
                    }, 
                    "name": "Clinical Investigative Site 000010"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14215"
                    }, 
                    "name": "Clinical Investigative Site 000011"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Clinical Investigative Site 00006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44095"
                    }, 
                    "name": "Clinical Investigative Site 00008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Clinical Investigative Site 00003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Clinical Investigative Site 000013"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22903"
                    }, 
                    "name": "Clinical Investigative Site 00001"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "24 hour Pharmacokinetic profile of LCP-Tacro vs Prograf on Days 1, 14 and 28 in adult de novo kidney recipients", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666951"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Comparison of 24-hour pharmacokinetic profiles, safety, pharmacodynamics (ambulatory blood pressure monitoring) and efficacy (death, graft failure and centrally read biopsy-proven acute rejection) of LCP-Tacro vs Prograf in 28 days.", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "source": "Veloxis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Veloxis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}